ME vs. PBYI, ACIU, AQST, IMMP, TSVT, ALDX, XBIT, VSTM, FHTX, and RENB
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Puma Biotechnology (PBYI), AC Immune (ACIU), Aquestive Therapeutics (AQST), Immutep (IMMP), 2seventy bio (TSVT), Aldeyra Therapeutics (ALDX), XBiotech (XBIT), Verastem (VSTM), Foghorn Therapeutics (FHTX), and Renovaro (RENB). These companies are all part of the "pharmaceutical preparations" industry.
23andMe (NASDAQ:ME) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
23andMe has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
23andMe presently has a consensus target price of $0.47, suggesting a potential downside of 4.59%. Puma Biotechnology has a consensus target price of $7.00, suggesting a potential upside of 45.83%. Given Puma Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Puma Biotechnology is more favorable than 23andMe.
Puma Biotechnology has lower revenue, but higher earnings than 23andMe. 23andMe is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Puma Biotechnology had 9 more articles in the media than 23andMe. MarketBeat recorded 17 mentions for Puma Biotechnology and 8 mentions for 23andMe. 23andMe's average media sentiment score of 0.49 beat Puma Biotechnology's score of 0.43 indicating that 23andMe is being referred to more favorably in the media.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 27.6% of 23andMe shares are owned by insiders. Comparatively, 22.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Puma Biotechnology received 524 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 66.58% of users gave Puma Biotechnology an outperform vote while only 63.16% of users gave 23andMe an outperform vote.
Puma Biotechnology has a net margin of 6.79% compared to 23andMe's net margin of -210.48%. Puma Biotechnology's return on equity of 35.49% beat 23andMe's return on equity.
Summary
Puma Biotechnology beats 23andMe on 15 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
